Teleflex Incorporated · NYSE:TFX
Teleflex — Investor Day (May 2022)
129 slides from Teleflex's investor day presentation, May 20, 2022
Slide 1: Teleflex Analyst & Investor Day 2022
ANALYST & INVESTOR DAY 2022 1. Teleflex Analyst & Investor Day 2022 Exhibit 99.2
Slide 2: Contents
ANALYST & INVESTOR DAY 2022 2. Welcome to Teleflex Analyst & Investor Day Lawrence Keusch, Vice President, Investor Relations & Strategy Development P. 3 Section 1: A Foundation for Durable Growth Delivering Long-Term Durable Growth Liam Kelly, Chairman, President & CEO P. 6 Corporate Social Respons
Slide 3: Welcome to Teleflex Analyst & Investor Day 2022
Welcome to Teleflex Analyst & Investor Day 2022 LAWRENCE KEUSCH | VICE PRESIDENT, INVESTOR RELATIONS & STRATEGY DEVELOPMENT | MAY 20, 2022 ANALYST & INVESTOR DAY 2022
Slide 4: Forward-Looking Statements
ANALYST & INVESTOR DAY 2022 4. Forward-Looking Statements Statements included in the following presentation, other than statements of historical fact, are “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995. The words “anticipate,” “b
Slide 5: Agenda
ANALYST & INVESTOR DAY 2022 5. Agenda 10:00 a.m. Welcome to Teleflex Analyst & Investor Day Lawrence Keusch, Vice President, Investor Relations & Strategy Development Section 1: A Foundation for Durable Growth 10:05 a.m. Delivering Long-Term Durable Growth Liam Kelly, Chairman, President & CEO Corpo
Slide 6: Delivering Long-Term Durable Growth
Building a Global Powerhouse in Emergency Medicine KEVIN ROBINSON | PRESIDENT & GENERAL MANAGER | MAY 20, 2022 ANALYST & INVESTOR DAY 2022 Delivering L ng-Term Durable Growth LIAM KELLY | CHAIRMAN, PRESIDENT & CEO | M Y 20, 2022 Return to contents
Slide 7: 7. 01. Building on Our Foundation 02. Strategic Drivers for Growth 03. Key Takeaways
ANALYST & INVESTOR DAY 2022 7. 01. Building on Our Foundation 02. Strategic Drivers for Growth 03. Key Takeaways
Slide 8: Building on Our Foundation
ANALYST & INVESTOR DAY 2022 8. 01. Building on Our Foundation
Slide 9: We are a Strong Company
ANALYST & INVESTOR DAY 2022 9. $2.8 billion in revenue Industry leading brands 23,000+ products* 120,000+ customers 14,000+ employees globally We are a Strong Company 01. Building on Our Foundation * Number of products calculated based on the number of stock keeping units offered by the company. Not
Slide 10: Our Industry Leading Brands
ANALYST & INVESTOR DAY 2022 10. Our Industry Leading Brands 01. Building on Our Foundation
Slide 11: We Prioritize Long-Term Growth
ANALYST & INVESTOR DAY 2022 11. We Prioritize Long-Term Growth ~85% revenue growth* 13.3% Adj. EPS CAGR* ~560 % total shareholder return* 80+ strategic acquisitions* 01. Building on Our Foundation * From 2011-2021 Note: See appendices for reconciliations of non-GAAP financial information.
Slide 12: Our Products Make a Difference Every Day
ANALYST & INVESTOR DAY 2022 12. Our Products Make a Difference Every Day 24,000 In over 24,000 surgical procedures in the United States 2,000 By Interventional Cardiologists, Radiologists, and Vascular Surgeons in over 2,000 patients who require vascular intervention 8,000 To care for more than 8,00
Slide 13: We Add Value Across Key Clinical Areas
ANALYST & INVESTOR DAY 2022 13. We Add Value Across Key Clinical Areas Comprehensive Vascular Access Specialty and Complex Catheters, Large Bore Femoral Arterial Access Site Closure Manual Clip Ligation and Surgical Instruments MIS treatment for BPH Emergency Medicine 01. Building on Our Foundation
Slide 14: Our Global Supply Chain is Best-In-Class
ANALYST & INVESTOR DAY 2022 14. Our Global Supply Chain is Best-In-Class 01. Building on Our Foundation 21 distribution centers 1,500+ suppliers ~9,0001 employees ~ 2M Sq. ft. manufacturing space ~$1B in spend Note: 1. Global supply chain employees, including support staff
Slide 15: We Put the Customer First
ANALYST & INVESTOR DAY 2022 15. We Put the Customer First 01. Building on Our Foundation
Slide 16: Strategic Drivers for Growth
ANALYST & INVESTOR DAY 2022 16. 02. Strategic Drivers for Growth
Slide 17: Teleflex Strategy 2023-2025: Deliver Long-Term Durable Growth
ANALYST & INVESTOR DAY 2022 17. 02. Strategic Drivers for Growth Teleflex Strategy 2023 – 2025: Deliver Long-Term Durable Growth 1. Drive sustainable revenue growth 2. Achieve margin and earnings expansion 3. Optimize our product portfolio 4. Advance corporate social responsibility and an inclusive
Slide 18: Teleflex Strategy 2023-2025
ANALYST & INVESTOR DAY 2022 18. 02. Strategic Drivers for Growth 1. Drive sustainable revenue growth 2. Achieve margin and earnings expansion 3. Optimize our product portfolio 4. Advance corporate social responsibility and an inclusive culture Teleflex Strategy 2023 – 2025: Deliver Long-Term Durable
Slide 19: Drive Sustainable Revenue Growth
ANALYST & INVESTOR DAY 2022 19. Drive Sustainable Revenue Growth High Growth Portfolio The UroLift® System, Hemostatic Products, Arrow® EZ-IO® Intraosseous Vascular Access System, PICC Portfolio, Arrow® OnControl® Powered Bone Access System, MANTA® Vascular Closure Device Durable Core Vascular Acces
Slide 20: High Growth Portfolio Early Penetration of Addressable Market
ANALYST & INVESTOR DAY 2022 20. High Growth Portfolio Early Penetration of Global Addressable Market Opportunity The UroLift® System: $12B+ Hemostatic Products: ~$600M Arrow® EZ-IO® Intraosseous Vascular Access System: ~$500M PICC Portfolio: $400M-$500M Arrow® OnControl® Powered Bone Access System:
Slide 21: Teleflex Strategy 2023-2025
ANALYST & INVESTOR DAY 2022 21. 02. Strategic Drivers for Growth 1. Drive sustainable revenue growth 2. Achieve margin and earnings expansion 3. Optimize our product portfolio 4. Advance corporate social responsibility and an inclusive culture Teleflex Strategy 2023 – 2025: Deliver Long-Term Durable
Slide 22: Achieve Margin and Earnings Expansion
ANALYST & INVESTOR DAY 2022 22. 02. Strategic Drivers for Growth Portfolio Mix High Growth portfolio will continue to drive margin expansion. UroLift 2, MANTA, hemostatic products, intraosseous, and PICCs Distributor to Direct Conversions Execute on our acquisition strategy, and reload on our opport
Slide 23: Teleflex Strategy 2023-2025
ANALYST & INVESTOR DAY 2022 23. 02. Strategic Drivers for Growth 1. Drive sustainable revenue growth 2. Achieve margin and earnings expansion 3. Optimize our product portfolio 4. Advance corporate social responsibility and an inclusive culture Teleflex Strategy 2023 – 2025: Deliver Long-Term Durable
Slide 24: Optimize our Product Portfolio
ANALYST & INVESTOR DAY 2022 24. 02. Strategic Drivers for Growth Strategic M&A and Divestitures Optimize our Product Portfolio New Product Introductions
Slide 25: Continued M&A Execution
ANALYST & INVESTOR DAY 2022 25. Continued M&A Execution Note: 1. From January 2011 to December 2021. Select Transactions Z-Medica 2020 Essential Medical 2018 HPC MEDICAL High Performance Conductors 2020 NeoTract 2017 Mini-Lap Technologies 2014 Vidacare 2013 Vascular Solutions 2017 80 deals closed1 $
Slide 26: Teleflex Strategy 2023-2025
ANALYST & INVESTOR DAY 2022 26. 02. Strategic Drivers for Growth 1. Drive sustainable revenue growth 2. Achieve margin and earnings expansion 3. Optimize our product portfolio 4. Advance corporate social responsibility and an inclusive culture Teleflex Strategy 2023 – 2025: Deliver Long-Term Durable
Slide 27: Advance Corporate Social Responsibility and an Inclusive Culture
ANALYST & INVESTOR DAY 2022 27. 02. Strategic Drivers for Growth Advance Corporate Social Responsibility and an Inclusive Culture Pillar I: Principles of Ethics & Governance Pillar II: Planet & Environment Pillar III: People Pillar IV: Prosperity & Sustainable Healthcare • Corporate Governance • Com
Slide 28: Key Takeaways
ANALYST & INVESTOR DAY 2022 28. 03. Key Takeaways
Slide 29: Teleflex Strategy 2023-2025
ANALYST & INVESTOR DAY 2022 29. 03. Key Takeaways Teleflex Strategy 2023 – 2025: Deliver Long-Term Durable Growth 1. Drive sustainable revenue growth 2. Achieve margin and earnings expansion 3. Optimize our product portfolio 4. Advance corporate social responsibility and an inclusive culture
Slide 30: Thank You
ANALYST & INVESTOR DAY 2022 30. Thank You
Slide 31: Corporate Social Responsibility
Building a Global Powerhouse in Emergency Medicine KEVIN ROBINSON | PRESIDENT & GENERAL MANAGER | MAY 20, 2022 ANALYST & INVESTOR DAY 2022 Corporate Social Responsibility AREN BOYLAN | CO PORATE VICE PRESIDENT, STRATEGIC PROJECTS | MAY 20, 2022 Return to contents
Slide 32: 32. 01. Strategic Overview 02. CSR Pillars 03. Key Takeaways
ANALYST & INVESTOR DAY 2022 32. 01. Strategic Overview 02. CSR Pillars 03. Key Takeaways
Slide 33: Strategic Overview
ANALYST & INVESTOR DAY 2022 33. 01. Strategic Overview
Slide 34: Teleflex Strategy 2023-2025
ANALYST & INVESTOR DAY 2022 34. Teleflex Strategy 2023 – 2025: Deliver Long-Term Durable Growth 1. Drive sustainable revenue growth 2. Achieve margin and earnings expansion 3. Optimize our product portfolio 4. Advance corporate social responsibility and an inclusive culture 01. Strategic Overview
Slide 35: CSR Pillars
ANALYST & INVESTOR DAY 2022 35. 02. CSR Pillars
Slide 36: CSR Pillars
ANALYST & INVESTOR DAY 2022 36. CSR Pillars 02. CSR Pillars Pillar I: Principles of Ethics & Governance Pillar II: Planet & Environment Pillar III: People Pillar IV: Prosperity & Sustainable Healthcare • Corporate Governance • Compliance, Integrity & Ethics • Sales & Marketing Practices • IT Securit
Slide 37: Ethics & Governance
ANALYST & INVESTOR DAY 2022 37. Ethics & Governance 02. CSR Pillars Increase Board Diversity • 33% of directors are women Global Compliance Program • Integrity Code, Code of Ethics and Anti-Corruption policies • Focused training Enterprise Risk Assessment • Online form for enhanced analytics
Slide 38: Planet & Environment
ANALYST & INVESTOR DAY 2022 38. 2021–2023 Global Operations Goals • 10 % Reduction in Purchased Energy • 10 % Reduction in Waste to Landfill Key Initiatives: • Solar Panels Projects at some global operations sites in Mexico, Malaysia and India • New Software to track consumption and output • New Sus
Slide 39: People
ANALYST & INVESTOR DAY 2022 39. People Continued COVID-19 Protocals • Global & Local Crisis Management Teams • Increased online employee training and development opportunities Cultivate Diversity, Equity & Inclusion • Established global and regional DEI councils • Expanded Inclusive leadership train
Slide 40: Prosperity & Sustainable Healthcare
ANALYST & INVESTOR DAY 2022 40. Product Training & Education Through in-person and online training, reached 130,000 HCPs in 2021 Teleflex Led Clinical Research UroLift® System Arrowg+ard Blue Advance™ PICCs Interventional CTO PCI Procedures Key Initiatives Expand Education and Research Grants Addres
Slide 41: Our Core Values
ANALYST & INVESTOR DAY 2022 41. 02. CSR Pillars Our Core Values Entrepreneurial Spirit • Be creative, take risks, and show initiative • Initiate change and innovation • Take ownership and be accountable Build Trust • Be sincere and authentic • Inform, ask, and listen • Be supportive and reliable Mak
Slide 42: Key Takeaways
ANALYST & INVESTOR DAY 2022 42. 03. Key Takeaways
Slide 43: Key Takeaways
ANALYST & INVESTOR DAY 2022 43. Key Takeaways • CSR roadmap outlines our environmental, governance and community targets • Our 2021 Global Impact Report will publish in Q3, 2022 • Our CSR program will help us attract and retain top talent 03. Key Takeaways
Slide 44: Thank You
ANALYST & INVESTOR DAY 2022 44. Thank You
Slide 45: Commercial's Role in Delivering Long-Term Durable Growth
Building a Global Powerhouse in Emergency Medicine KEVIN ROBINSON | PRESIDENT & GENERAL MANAGER | MAY 20, 2022 ANALYST & INVESTOR DAY 2022 Commercial’s Role in D livering Long-Term Durabl Growth JAY WHITE | C RPORATE VICE PRESID NT & PRESID NT, GLOBAL COMMERCIAL | MAY 20, 2022 Return to contents
Slide 46: 46. 01. Commercial’s Role in Driving Long-Term Durable Growth 02. Commercial’s Targeted Growth Opportunities
ANALYST & INVESTOR DAY 2022 46. 01. Commercial’s Role in Driving Long-Term Durable Growth 02. Commercial’s Targeted Growth Opportunities 03. Key Takeaways
Slide 47: Commercial's Role in Driving Long-Term Durable Growth
ANALYST & INVESTOR DAY 2022 47. 01. Commercial’s Role in Driving Long-term Durable Growth
Slide 48: Teleflex Strategy 2023-2025
ANALYST & INVESTOR DAY 2022 48. Teleflex Strategy 2023 – 2025: Deliver long-term durable growth 01. Commercial’s Role in Driving Long-Term Durable Growth 1. Drive sustainable revenue growth 2. Achieve margin and earnings expansion 3. Optimize our Product Portfolio 4. Advance corporate social respons
Slide 49: Commercial's Targeted Growth Opportunities
ANALYST & INVESTOR DAY 2022 49. 02. Commercial’s Targeted Growth Opportunities
Slide 50: Building Durable Growth
ANALYST & INVESTOR DAY 2022 50. Building Durable Growth 02. Commercial’s Targeted Growth Opportunities Note: Dark blue bars show total Teleflex revenue and percentages included above those show year-over-year growth rates. 2017 2018 2019 2020 7.0% CAGR 2017-2021 2021 14.9% 14.1% 6.0 % (2.2%) 10.7 %
Slide 51: Three Key Growth Opportunities
ANALYST & INVESTOR DAY 2022 51. 02. Commercial’s Targeted Growth Opportunities Three Key Growth Opportunities Drive market leading durable growth through a focused approach 1. Globalization in Key Markets 2. Optimize our Product Portfolio 3. Expand Market Share with High Growth Franchises
Slide 52: Three Key Growth Opportunities
ANALYST & INVESTOR DAY 2022 52. 02. Commercial’s Targeted Growth Opportunities Three Key Growth Opportunities Drive market leading durable growth through a focused approach 1. Globalization in Key Markets 2. Optimize our Product Portfolio 3. Expand Market Share with High Growth Franchises
Slide 53: Globalization in Key Markets | The Opportunity
ANALYST & INVESTOR DAY 2022 53. 02. Commercial’s Targeted Growth Opportunities Globalization in Key Markets | The Opportunity Americas EMEA Asia OEM 2021 Total Revenue by Segment 9 % 10% 22 % 59 %$ 1,659 M $ 607 M $ 298 M $ 246 M
Slide 54: Globalization in Key Markets | Areas of Focus
ANALYST & INVESTOR DAY 2022 54. 02. Commercial’s Targeted Growth Opportunities 3 1 2 Globalization in Key Markets | Areas of Focus Focused Approach to Accelerate Growth Strengthen Sales Channel in Key Growth Markets Enhance Customer Experience
Slide 55: Three Key Growth Opportunities
ANALYST & INVESTOR DAY 2022 55. 02. Commercial’s Targeted Growth Opportunities Three Key Growth Opportunities Drive market leading durable growth through a focused approach 1. Globalization in Key Markets 2. Optimize our Product Portfolio 3. Expand Market Share with High Growth Franchises
Slide 56: Optimizing our Product Portfolio | Areas of Focus
ANALYST & INVESTOR DAY 2022 56. 02. Commercial’s Targeted Growth Opportunities Optimizing our Product Portfolio | Areas of Focus Strategic M&A and Divestitures New Product Introductions
Slide 57: New Product Highlights | Interventional Urology
ANALYST & INVESTOR DAY 2022 57. 02. Commercial’s Targeted Growth Opportunities New Product Highlights | Interventional Urology UroLift® 2 System UroLift ATC® Advanced Tissue Control System
Slide 58: New Product Highlights | Interventional
ANALYST & INVESTOR DAY 2022 58. 02. Commercial’s Targeted Growth Opportunities Note: GuideLiner® Coast, Ringer® and Wattson® are not approved for sale or distribution. Ringer®GuideLiner® Coast Wattson® New Product Highlights | Interventional
Slide 59: New Product Highlights | Vascular Access
ANALYST & INVESTOR DAY 2022 59. 02. Commercial’s Targeted Growth Opportunities Arrowg+ard Blue Advance® Midline Arrow® ErgoPack® Complete CVC System Arrow® VPS Rhythm® DLX with TipTracker™ Technology Note: Arrow® VPS Rhythm® DLX with TipTracker™ Technology is not approved for sale or distribution. N
Slide 60: Three Key Growth Opportunities
ANALYST & INVESTOR DAY 2022 60. 02. Commercial’s Targeted Growth Opportunities Three Key Growth Opportunities Drive market leading durable growth through a focused approach 1. Globalization in Key Markets 2. Optimize our Product Portfolio 3. Expand Market Share with High Growth Franchises
Slide 61: Significant Global UroLift Market Opportunity
ANALYST & INVESTOR DAY 2022 61. Note: Global includes key countries such as Brazil, China, Germany, France, India, Italy, Japan, Spain, Taiwan Source: Teleflex internal market estimates 02. Commercial’s Targeted Growth Opportunities Significant Global UroLift® Market Opportunity U.S. Non-U.S. $ 6 B
Slide 62: Extensive Clinical Evidence Supports UroLift System
ANALYST & INVESTOR DAY 2022 62. 02. Commercial’s Targeted Growth Opportunities Extensive Clinical Evidence Supports UroLift® System “The outcomes from the numerous studies are consistent, demonstrating rapid relief within two weeks and sustained improvement in symptoms, quality of life and urinary f
Slide 63: Expand Market Share with High Growth Franchises: Interventional
ANALYST & INVESTOR DAY 2022 63. Expand Market Share with High Growth Franchises Interventional MANTA® Vascular Closure Device Arrow® OnControl® Powered Bone Access System 02. Commercial’s Targeted Growth Opportunities
Slide 64: Expand Market Share with High Growth Franchises: Anesthesia
ANALYST & INVESTOR DAY 2022 64. Expand Market Share with High Growth Franchises Anesthesia Arrow® EZ-IO® Intraosseous Vascular Access System QuikClot® Hemostatic Products 02. Commercial’s Targeted Growth Opportunities
Slide 65: Expand Market Share with High Growth Franchises: Vascular Access
ANALYST & INVESTOR DAY 2022 65. Expand Market Share with High Growth Franchises Vascular Access Arrow® VPS Rhythm® DLX with TipTracker™ Technology 02. Commercial’s Targeted Growth Opportunities Arrowg+ard Blue Advance® PICC Note: Arrow® VPS Rhythm® DLX with TipTracker™ Technology is not approved for
Slide 66: Durable Core Products
ANALYST & INVESTOR DAY 2022 66. GuideLiner®Arrowg+Blue Plus® CVC Turnpike® Hem-o-lok®IAB® 02. Commercial’s Targeted Growth Opportunities Durable Core Products
Slide 67: Key Takeaways
ANALYST & INVESTOR DAY 2022 67. 03. Key Takeaways
Slide 68: Drive Market Leading Durable Growth Through Focused Approach
ANALYST & INVESTOR DAY 2022 68. Drive Market Leading Durable Growth Through Focused Approach 03. Key Takeaways • We can deliver durable and sustainable growth • We have multiple regions, sites of services and products to drive our strategy • We will execute against three growth opportunities • Globa
Slide 69: Thank You
ANALYST & INVESTOR DAY 2022 69. Thank You
Slide 70: Empowering Long-Term Durable Growth: Global Supply Chain
Building a Global Powerhouse in Emergency Medicine KEVIN ROBINSON | PRESIDENT & GENERAL MANAGER | MAY 20, 2022 ANALYST & INVESTOR DAY 2022 Empowering Long-Term Durable Growth Global Supply Chai JAMES WINTERS | CO PORATE VICE PRESIDENT, MANUFACTURING & SUPPLY CHAIN | MAY 20, 2022 Teleflex Site, Kulim
Slide 71: 71. 01. Global Supply Chain Footprint 02. Global Supply Chain Pillars for Long-Term Durable
ANALYST & INVESTOR DAY 2022 71. 01. Global Supply Chain Footprint 02. Global Supply Chain Pillars for Long-Term Durable Growth 03. Key Takeaways
Slide 72: Global Supply Chain Footprint
ANALYST & INVESTOR DAY 2022 72. 01. Global Supply Chain Footprint
Slide 73: Our Global Footprint
ANALYST & INVESTOR DAY 2022 73. Our Global Footprint 01. Global Supply Chain Footprint 21 distribution centers 1,500+ suppliers ~9,0001 employees ~ 2M Sq. ft. manufacturing space ~$1B in spend Note: 1. Global supply chain employees, including support staff.
Slide 74: Global Supply Chain Pillars for Long-Term Durable Growth
ANALYST & INVESTOR DAY 2022 74. 02. Global Supply Chain Pillars for Long-Term Durable Growth
Slide 75: Teleflex Strategy 2023-2025
ANALYST & INVESTOR DAY 2022 75. Teleflex Strategy 2023 – 2025: Deliver Long-Term Durable Growth 1. Drive sustainable revenue growth 2. Achieve margin and earnings expansion 3. Optimize our product portfolio 4. Advance corporate social responsibility and an inclusive culture 02. Global Supply Chain P
Slide 76: Our Global Supply Chain Vision
ANALYST & INVESTOR DAY 2022 76. Together we will build a best-in-class end-to-end supply chain as recognized by our customers and business partners Our Global Supply Chain Vision 02. Global Supply Chain Pillars for Long-Term Durable Growth
Slide 77: Global Supply Chain Strategy
ANALYST & INVESTOR DAY 2022 77. Global Supply Chain Strategy 02. Global Supply Chain Pillars for Long-Term Durable Growth High Performing Leadership and Culture Position for Durable Growth Gross Margin Expansion Enterprise Excellence Relentless Focus on Product Quality Sustainability
Slide 78: Position for Durable Growth
ANALYST & INVESTOR DAY 2022 78. Position for Durable Growth Advanced Analytics Global Command Center Net Promoter Score (NA) ~15% Improvement Q4 2021 compared to Q4 2020 02. Global Supply Chain Pillars for Long-Term Durable Growth End-to-End Supply Chain Assessment >$48M invested from 2018-2021 to i
Slide 79: Margin Expansion Goals
ANALYST & INVESTOR DAY 2022 79. 02. Global Supply Chain Pillars for Long-Term Durable Growth 1. Company data on file. Margin Expansion Goals ~80% of revenue sourced from geographies that are optimized for Teleflex’s cost structure by 2025 $24-$28M1 in savings from existing restructuring programs bet
Slide 80: Enterprise Excellence
ANALYST & INVESTOR DAY 2022 80. Enterprise Excellence Cost Improvement Programs exceeded inflation 2018–2021 2018 CIPs Inflation2019 2020 2021 Cost Improvement Programs CIPs vs Inflation 2018–2021 Customers Employees Management Leader Servant Leadership 02. Global Supply Chain Pillars for Long-Term
Slide 81: Relentless Focus on Product Quality
ANALYST & INVESTOR DAY 2022 81. Relentless Focus on Product Quality 02. Global Supply Chain Pillars for Long-Term Durable Growth 2020 vs. 2021 • 18% year-over-year declines in scrap 2018 vs. 2021 • 38% reduction in the number of field corrective actions • 55% reduction in ship holds
Slide 82: Sustainability in Global Supply Chain
ANALYST & INVESTOR DAY 2022 82. Sustainability in Global Supply Chain 10 % reduction in our waste sent to landfill Operational Goals 2021 - 2023 10 % reduction in purchased energy 02. Global Supply Chain Pillars for Long-Term Durable Growth
Slide 83: High Performing Leadership and Culture
ANALYST & INVESTOR DAY 2022 83. High Performing Leadership and Culture 02. Global Supply Chain Pillars for Long-Term Durable Growth
Slide 84: Key Takeaways
ANALYST & INVESTOR DAY 2022 84. 03. Key Takeaways
Slide 85: Enable Long-Term Durable Growth
ANALYST & INVESTOR DAY 2022 85. 03. Key Takeaways Enable Long-Term Durable Growth • Supply chain resilience and flexibility • $24-$28M1 in expected incremental cost savings from existing restructuring programs between 2023-2025 • Maintain the highest standards for product quality • Leverage Enterpri
Slide 86: Thank You
ANALYST & INVESTOR DAY 2022 86. Thank You
Slide 87: Clinical Panel Overview
Building a Global Powerhouse in Emergency Medicine KEVIN ROBINSON | PRESIDENT & GENERAL MANAGER | MAY 20, 2022 ANALYST & INVESTOR DAY 2022 Clinical Panel Overview MICHELLE FOX | CORPORATE VICE PR SIDENT & CHIEF MEDICAL OFFICER | MAY 20, 2022 Return to contents
Slide 88: Clinical and Medical Affairs Led Design of Clinical Development Programs
ANALYST & INVESTOR DAY 2022 88. Clinical and Medical Affairs Led the Design and Implementation of Clinical Development Programs • Teleflex Academy, across 88 countries • 56,000 continuing education credits • We reached more than 130,000 healthcare professionals in 2021 • Human Factors welcomed into
Slide 89: Clinician Disclosures
ANALYST & INVESTOR DAY 2022 89. Clinician Disclosures • Dr. Matt Ashley, Dr. Gregg R. Eure and Dr. Matthew Summers are paid to consults for Teleflex Incorporated • The opinions expressed by these clinicians are their own and do not necessarily reflect the views of Teleflex Incorporated
Slide 90: Thank You
ANALYST & INVESTOR DAY 2022 90. Thank You
Slide 91: Interventional Urology Clinical Panel
Interventional Urology Clinical Panel KEVIN HARDAGE | PRESIDENT & GENERAL MANAGER, INTERVENTIONAL UROLOGY | MAY 20, 2022 ANALYST & INVESTOR DAY 2022 Return to contents
Slide 92: Interventional Urology
ANALYST & INVESTOR DAY 2022 92. Interventional Urology Innovative delivery system that reduces packaging waste and streamlines the procedure1 with the same implant with proven outcomes. Enhanced delivery device tip for treating BPH patients with challenging anatomies, including an obstructive median
Slide 93: Thank You
ANALYST & INVESTOR DAY 2022 93. Thank You
Slide 94: Interventional Clinical Panel
Building a Global Powerhouse in Emergency Medicine KEVIN ROBINSON | PRESIDENT & GENERAL MANAGER | MAY 20, 2022 ANALYST & INVESTOR DAY 2022 Interventional Clinical Panel SCOTT H LSTINE | PRESI E T & E ERAL A A ER, INTERVENTIONAL | MAY 20, 2022 Return to contents
Slide 95: Interventional: Who We Are
ANALYST & INVESTOR DAY 2022 95. Interventional Who We Are Coronary Interventions GuideLiner® V3 Catheter Turnpike® Catheters Structural Heart MANTA® Vascular Closure Device Mechanical Circulatory Support Arrow® AC3 Optimus® Intra-Aortic Balloon Pump Intra-Aortic Balloon Catheters Peripheral Interven
Slide 96: Thank You
ANALYST & INVESTOR DAY 2022 96. Thank You
Slide 97: Financial Overview & Presentation of the 3-Year LRP
Building a Global Powerhouse in Emergency Medicine KEVIN ROBINSON | PRESIDENT & GENERAL MANAGER | MAY 20, 2022 ANALYST & INVESTOR DAY 2022 Financial Overview & Pr sentation of the 3-Year LRP THOMAS POWELL EX CUTIVE VIC PRESIDENT & CHIEF FINANCIAL OFFICER | MAY 20, 2022 Return to contents
Slide 98: 98. 01. Teleflex Has Delivered For Shareholders 02. Reaffirming 2022 Financial Guidance 03. Looking
ANALYST & INVESTOR DAY 2022 98. 01. Teleflex Has Delivered For Shareholders 02. Reaffirming 2022 Financial Guidance 03. Looking Ahead – Value Creation Framework 04. Key Takeaways
Slide 99: Teleflex Has Delivered For Shareholders
ANALYST & INVESTOR DAY 2022 99. 01. Teleflex Has Delivered For Shareholders
Slide 100: Teleflex has Delivered for Shareholders
ANALYST & INVESTOR DAY 2022 100.1. Average Annual Constant Currency Growth 2. Total return includes stock price appreciation and dividends from December 31, 2011 to December 31,2021. Note: See appendices for reconciliations of non-GAAP financial information. 01. Teleflex Has Delivered For Shareholde
Slide 101: Reaffirming 2022 Financial Guidance
ANALYST & INVESTOR DAY 2022 101. 02. Reaffirming 2022 Financial Guidance
Slide 102: Reaffirming 2022 Financial Guidance
ANALYST & INVESTOR DAY 2022 102. 1. Constant currency growth includes a 1.5% headwind for the divestiture of the respiratory assets. Note: See appendices for reconciliations of non-GAAP financial information. 3 1 2 4 01. Reaffirming 2022 Financial Guidance Reaffirming 2022 Financial Guidance Constan
Slide 103: Looking Ahead – Value Creation Framework
ANALYST & INVESTOR DAY 2022 103. 03. Looking Ahead – Value Creation Framework
Slide 104: Teleflex Value Creation Framework: 2023-2025
ANALYST & INVESTOR DAY 2022 104. 03. Looking Ahead – Value Creation Framework 1. As of end of Q1 2022 2. Three year CAGR from 2023 to 2025, with year-end 2022 as base year. 3. Base year is 2022 year end adj. margin Note: See appendices for reconciliations of non-GAAP financial information. Disciplin
Slide 105: Financial Outlook Key Assumptions: 2023-2025
ANALYST & INVESTOR DAY 2022 105. Outlook Assumes Outlook Does Not Assume 03. Looking Ahead – Value Creation Framework Financial Outlook Key Assumptions: 2023 - 2025 Volume growth in base business Material changes to global regulatory or macroeconomic environment New product revenue growth contributi
Slide 106: Constant Currency Revenue Growth Outlook: 2023-2025
ANALYST & INVESTOR DAY 2022 106.1. Three year CAGR from 2023 to 2025, with year-end 2022 as base year. 2. Other includes urology, remaining respiratory products post-divestiture, and MSA revenue associated with respiratory divestiture to Medline. Each bar represents Teleflex total revenue dollars. T
Slide 107: Adjusted Gross Margin Expansion Objectives: 2023-2025
ANALYST & INVESTOR DAY 2022 107.Note: See Appendices for reconciliation of non-GAAP financial information. 1. Long range plan gross margin expansion, base year is 2022. 03. Looking Ahead – Value Creation Framework Adjusted Gross Margin Expansion Objectives: 2023 - 2025 2011 2022 2025 47.6% 59.75 % -
Slide 108: Restructuring Plans Support Margin Expansion
ANALYST & INVESTOR DAY 2022 108. 1. Company data on file. 03. Looking Ahead – Value Creation Framework Restructuring Plans Support Margin Expansion ~$125M 2014-2021 $24-$28M 2023-2025 $21-$23M 2022 Anticipated Pre-Tax Savings1 Pre-tax Savings1 Track record of generating non-revenue dependent margin
Slide 109: Adjusted Operating Margin Expansion Objectives: 2023-2025
ANALYST & INVESTOR DAY 2022 109. Note: See Appendices for reconciliation of non-GAAP financial information. 1. Long range plan operating margin expansion, base year is 2022. 03. Looking Ahead – Value Creation Framework Adjusted Operating Margin Expansion Objectives: 2023 - 2025 2011 2022 2025 19.0%
Slide 110: Free Cash Flow Growth Objectives: 2023-2025
ANALYST & INVESTOR DAY 2022 110. 03. Looking Ahead – Value Creation Framework 1. $1.26 billion, rounded. Note: See appendices for reconciliation of non-GAAP financial information. Free Cash Flow Growth Objectives: 2023-2025 2019 - 2021 2023 - 2025 $1.3 billion1 At least $1.7 billion Cumulative Free
Slide 111: Disciplined Capital Allocation Framework
ANALYST & INVESTOR DAY 2022 111. 03. Looking Ahead – Value Creation Framework Disciplined Capital Allocation Framework Internal Investment Strategic M&A Debt Repayment Cash to Shareholders • For high-ROI growth drivers and restructuring activities • Deployment of capital for growth and margin accret
Slide 112: Key Takeaways
ANALYST & INVESTOR DAY 2022 112. 04. Key Takeaways
Slide 113: Key Takeaways
ANALYST & INVESTOR DAY 2022 113. 04. Key Takeaways 1. Three year CAGR from 2023 to 2025, with year-end 2022 as the base year. 2. Long range plan operating margin expansion, base year is 2022. Note: See appendices for reconciliations of non-GAAP financial information. Key Takeaways • 6-7% constant cu
Slide 114: Question and Answer Session
ANALYST & INVESTOR DAY 2022 114. Question and Answer Session
Slide 115: Appendices
ANALYST & INVESTOR DAY 2022 115. Appendices
Slide 116: Note on Non-GAAP Financial Measures
ANALYST & INVESTOR DAY 2022 116. Note on Non-GAAP Financial Measures The presentation to which these appendices are attached, and the following appendices include, among other things, tables reconciling the following applicable non-GAAP financial measures to the most comparable GAAP financial measur
Slide 117: Non-GAAP Adjustments
ANALYST & INVESTOR DAY 2022 117. Non-GAAP Adjustments The following is an explanation of certain of the adjustments that are applied with respect to one or more of the non-GAAP financial measures that appear in the presentation to which these appendices are attached: • Restructuring, restructuring r
Slide 118: Non-GAAP Adjustments
ANALYST & INVESTOR DAY 2022 118. Non-GAAP Adjustments • MDR Costs. The European Union (“EU”) has adopted the EU Medical Device Regulation (“MDR”), which replaces the existing Medical Devices Directive (“MDD”) and imposes more stringent requirements for the marketing and sale of medical devices in th
Slide 119: Appendix A – Reconciliation of Constant Currency Revenue Growth, 2012-2019
ANALYST & INVESTOR DAY 2022 119. Appendix A – Reconciliation of Constant Currency Revenue Growth, 2012-2019 Dollars in Millions
Slide 120: Appendix B – Reconciliation of Adjusted Gross Profit and Margin
ANALYST & INVESTOR DAY 2022 120. Appendix B – Reconciliation of Adjusted Gross Profit and Margin Dollars in Thousands Twelve Months Ended Margin Expansion 12/31/11 12/31/21 2011-2021 Gross profit as-reported 708,778$ 1,549,602$ Gross margin as-reported 47.5% 55.2% 7.7% Restructuring, restructuring r
Slide 121: Appendix C – Reconciliation of Adjusted Operating Profit and Margin
ANALYST & INVESTOR DAY 2022 121. Appendix C – Reconciliation of Adjusted Operating Profit and Margin Dollars in Thousands Twelve Months Ended Margin Expansion 12/31/11 12/31/21 2011-2021 Income from continuing operations before interest, loss on extinguishment of debt and taxes 229,570$ 628,095$ Inc
Slide 122: Appendix D – Reconciliation of Adjusted Earnings per Share
ANALYST & INVESTOR DAY 2022 122. Appendix D – Reconciliation of Adjusted Earnings per Share Twelve Months Ended 12/31/11 12/31/21 GAAP diluted earnings per share available to common shareholders 2.90$ 10.23$ GAAP EPS compounded annual growth rate 2011-2021 CAGR 13.4% Restructuring, restructuring rel
Slide 123: Appendix D – Tickmarks
ANALYST & INVESTOR DAY 2022 123. Appendix D – Tickmarks A. Restructuring, restructuring related and impairment items – For the year ended December 31, 2021, pre-tax restructuring charges were $15.0 million, pre-tax restructuring related charges were $31.2 million; and pre-tax impairment charges were
Slide 124: Appendix E – Reconciliation of Free Cash Flow 2019-2021
ANALYST & INVESTOR DAY 2022 124. Appendix E – Reconciliation of Free Cash Flow 2019-2021 Dollars in Millions
Slide 125: Appendix F – Reconciliation of Forecasted Free Cash Flow 2023-2025
ANALYST & INVESTOR DAY 2022 125. Appendix F – Reconciliation of Forecasted Free Cash Flow 2023-2025 Dollars in Millions 2023 to 2025 Cumulative Forecasted net cash provided by operating activities from continuing operations 1,980$ Less: Forecasted capital expenditures 280$ Forecasted Free Cash Flow
Slide 126: Appendix G – Reconciliation of 2022 Constant Currency Revenue Growth Guidance
ANALYST & INVESTOR DAY 2022 126. Appendix G – Reconciliation of 2022 Constant Currency Revenue Growth Guidance
Slide 127: Appendix H - 2022 Adj. Gross and Operating Margin Guidance Reconciliation
ANALYST & INVESTOR DAY 2022 127. Appendix H - 2022 Adj. Gross and Operating Margin Guidance Reconciliation Low High Forecasted GAAP Gross Margin 55.85% 56.35% Estimated restructuring, restructuring related and impairment items 0.90% 0.90% Estimated acquisition, integration, and divestiture related i
Slide 128: Appendix I – Reconciliation of 2022 Adjusted Earnings Per Share Guidance
ANALYST & INVESTOR DAY 2022 128. Appendix I – Reconciliation of 2022 Adjusted Earnings Per Share Guidance Low High Forecasted GAAP Diluted Earnings Per Share from continuing operations $8.85 $9.45 Estimated restructuring, restructuring related and impairment items, net of tax $0.76 $0.76 Estimated a
Slide 129: Thank You
ANALYST & INVESTOR DAY 2022 129. Thank You